We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0Q15 market cap is 98.86B. The company's latest EPS is USD 7.7269 and P/E is 16.68.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 34.61B | 43.08B | 43.65B | 40.11B | 41.95B |
| Operating Income | 5.36B | 8.43B | 8.36B | 6.48B | 6.83B |
| Net Income | 4.5B | 7.07B | 6.93B | 5.72B | 13.4B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 72.55B | 75.2B | 74.44B | 73.21B | 81.41B |
| Total Liabilities | 39.55B | 39.17B | 37.53B | 34.39B | 33.51B |
| Total Equity | 33B | 36.02B | 36.91B | 38.83B | 47.9B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 7.9B | 10.53B | 9.58B | 7.26B | 8.56B |
| Investing | -2.22B | -2.01B | -1.74B | -3.13B | -2.34B |
| Financing | -2.78B | -5.49B | -7.64B | -7.09B | -5.4B |
| Market Cap | 98.86B |
| Price to Earnings Ratio | 16.68 |
| Price to Sales Ratio | 5.33 |
| Price to Cash Ratio | 29.34 |
| Price to Book Ratio | 4.67 |
| Dividend Yield | - |
| Shares Outstanding | 1.73B |
| Average Volume (1 week) | 1.8k |
| Average Volume (1 Month) | 4.52k |
| 52 Week Change | 0.00% |
| 52 Week High | 57.00 |
| 52 Week Low | 57.00 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Abbott Laboratories |
| Address |
208 so lasalle st chicago, illinois 60604-1101 |
| Website | https://www.abbott.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
